The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

ZURICH (Reuters) -Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from the tariff wars, Maggie Fick of ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

aUNDP–UNFPA–UNICEF–WHO–World Bank Special Programme of Research, Development, and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, WHO, Geneva, ...

O deputado federal Guilherme Boulos (PSOL-SP) apareceu como cotado a assumir alguma pasta na Esplanada. Realmente, o presidente Luiz Inácio Lula da Silva prepara mudanças em ministérios, mas o ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly ...

This is centered on its hotly popular drug Wegovy. Before market open, Novo Nordisk announced the launch of its NovoCare Pharmacy, a direct-to-patient delivery service for its best-selling Wegovy ...

Less than two weeks after Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk said Wednesday it would cut the price of its popular weight-loss drug Wegovy ...